[1] U.S. Food and Drug Administration. Positron Emission Tomography (PET): Questions and Answers about CGMP Regulations for PET Drugs[EB/OL].(2009-12-9)[2012-4-30]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm193476.htm.
[2] 金征宇. 医学影像学[M]. 第2版.北京:人民卫生出版社,2010:20.
[3] 张锦明, 田嘉禾. 国内正电子放射性药物发展现状简介[J]. 同位素,2006,19(4):240.
[4] 国家食品药品监督管理局,卫生部. 医疗机构制备正电子类放射性药品管理规定[EB/OL]. (2006-1-5)[2012-4-30]. http://www.sda.gov.cn/WS01/CL0058/9355.html.
[5] Ido T, Wan CN, Fowler JS, et al. Fluorination with F2:convenient synthesis of 2-deoxy-2-fluoro-D-glucose[J] J Org Chem,1977,42: 2341.
[6] Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution[J]. J Nucl Med,1986,27:235.
[7] Fuchtner F, Steinbach J, Mading P. Basic previous term hydrolysis next term 2-[18F]fluoro-1,3,4,6-tetra-O-acetyl-image-glucose in the preparation of 2-[18F]fluoro-2-deoxy-Image-glucose[J]. Appl Radiat Isot,1996,47:61.
[8] Shankar V, Lilja S, Brigitte V. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new?[J]. Semin Nucl Med,2011, 41: 246.
[9] International Atomic Energy Agency. Nuclear Technology Review 2010[R/OL].(2010-8-10)[2012-4-30].http://www.iaea.org/About/Policy/GC/GC54/GC54InfDocuments/English/gc54inf-3_en.pdf.
[10] U.S. Food and Drug Administration. Drug information[DB/OL]. [2012-4-30]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
[11] 中华医学会核医学分会. 2010年全国核医学现状普查[J].中华核医学杂志,2010,30(6):428.
[12] 梁银杏,叶 桦. 关于我国正电子放射性药品新药注册管理的建议[J]. 中国新药与临床杂志,2012,31(2):68.
[13] 张锦明. 正电子放射性药物进展[J]. 中华核医学杂志,2003,23(5):315.
[14] 周 克,杨 勤,向 燕. 正电子放射性药物的现状与进展[J]. 西南军医,2005,7(2):47.
[15] 卫生部. 中华人民共和国卫生部批准配置PET/CT医疗机构名单[J]. 中华核医学杂志,2010,30(6):418.
[16] 卫生部. 2011~2015年全国正电子发射型断层扫描仪配置规划 [EB/OL].(2011-11-2)[2012-4-30]http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohghcws/s3585/201111/53257.htm.
[17] 国家食品药品监督管理局,卫生部. 正电子类放射性药品质量控制指导原则[EB/OL].(2006-1-5)[2012-4-30]. http://www.sda.gov.cn/WS01/CL0058/9355_6.html.
[18] USP 32-NF 27[S]. 2008: 2406.